Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Nice on WAVE augusta! Might consider some Chinese faves all profitable and growing rapidly also (I'm in all of these btw): CREG CHGI CYXN NEWN...not sure TA wise how they'd rate but these are up and comers imho based on fundamentals...all the best! tuna
Yeah bb...at least I'll get it over with early and not have to be thinking about all day first...of course I'm doing that worrying today...haha! Can't avoid it I guess...tuna
No bb, CREG closed in the 5.60's...still confident for tomorrow...have a great night! I have to have a root canal done early in the morning so won't be around the first 2 hours or so...ugh! tuna
Thanks...my gut says CREG rallies 3 days...but I've surely been wrong so many times before...haha! Best of luck if you try it again bb...tuna
CREG 5.79 +.61 will we see 5.80's close?
CHGI 2.77 x 2.79 and NEWN 7.17 x 7.23 ut'ing here!!
Chinese CREG 5.70's moving back up again w/6.16 HOD and 52wk high reached earlier today on huge volume!! tuna
I would have filled CREG at 5.66 bb...may have bottomed now before the next leg up imho...tuna
5.60's may be bottom for Chinese CREG before moving higher imho...tuna
CIGX 2.60 +.32 on huge volume has been on an unbelievable run of 17 up days in the last 18!!! Wow!!! tuna
CIGX 2.60 +.32 HOD on massive volume!!
CYXN .60 +.05 new HOD w/.16 estimated '09 earnings still one of the best bargains out there in Chinese stock land imho...tuna
CIGX 2.57 +.29 nearing HOD on a huge run the past month!!!
Chinese CYXN .59 x .60 highest bid/ask of the day! With .16 earnings estimated for '09 at .60 is still a PE of 3!!! tuna
Chinese CHGI 2.79 +.10 New HOD!!
Moved up the CREG bid to 5.75 and filled bb...hope the extra buy serves well...tuna
CGAQ .10 +.006 pretty steady between .095 and .105 worth so much more imho with a PE of less than 10....tuna
Yeah bb, CYXN .59 +.04 at HOD another Chinese bargain in my book! Btw, I missed CREG by a penny as it dropped to 5.67 a few minutes back...I may well get it though yet today...best of luck! tuna
Chinese CHGI 2.78 +.09 new HOD!!
Chinese CHGI 2.75 x 2.78 a buy at the ask would be a new HOD!!
Order in for CREG at 5.66 bb...2k shares...just has to drop another .12 on the bid for me to show! tuna
Good way to go BRIG!! CREG 5.87 +.69 today is another one of my Chinese stocks that went onto NASDAQ Monday and dropped til taking off today on massive volume, likely the most in the stock's trading history today!! I'm guessing institutions and funds adding it due to it's strong earnings and revenue growth reported last week! All the best!! tuna
bb, might check Chinese CYXN .59 w/pe 3!!! Estimated to earn .16 for '09!! Added more again today...been adding some for a week now...tuna
CREG 5.70's on the bid now...coming back as you predicted bb...I'll add more in the 5.60's...tuna
I like LIWA! Also In Chinese CYXN .59 +.03 w/.16 net income for '09 estimated:
China Yongxin Pharmaceuticals Projects Higher Net Income and EPS on Reduced Revenue for Full-Year 2009
Year End Will Show Higher Gross Profit and Margins Due to Change in Strategy
Press Release Source: China Yongxin Pharmaceuticals, Inc. On Thursday December 31, 2009, 8:00 am EST
CHANGCHUN, China and LOS ANGELES, Dec. 31 /PRNewswire-Asia/ -- China Yongxin Pharmaceuticals, Inc. (OTC Bulletin Board: CYXN; "China Yongxin Pharmaceuticals" or the "Company"), a leading manufacturer, distributor and retailer of Chinese traditional medicines, pharmaceutical products, natural health products, health food, cosmetics, and medical equipment in Northeastern China, today announced its projected financial results for the year ending December 31, 2009.
Revenues for the full-year 2009 are projected to be $46.1 million, a 22% decrease from $59.1 million for 2008. The decrease in total revenue is due to the transition of the Company's sales strategy, which, because of the uncertain direction of the National Medical Policy, has been refocused from the wholesale sector to the retail and medical facilities sector. While a broader product portfolio and expanded marketing activities increased 2009 revenues from the Company's retail drug stores by approximately 30% over the prior year, it was not sufficient to completely offset the decrease in the Company's wholesale business, resulting in comparably lower total net revenue.
For 2009, net income is projected to be approximately $5.4 million, a 35% increase over the $4.1 million for 2008. The increase primarily is related to higher margin retail and medical facilities sales.
The Company expects to report that diluted earnings per share increased to $0.16 for 2009 compared to $0.13 for 2008, based on 34.4 million and 31.2 million shares respectively. Provision for income tax in 2009 is $2.7 million compared to $1 million in 2008.
Mr. Yongxin Liu, Chairman and Chief Executive Officer of China Yongxin, commented that during 2009, the Company's wholesale business was impacted by customers waiting for specifics on the new healthcare reform plan. "However, on August 18th, the Chinese government issued China's Essential Drug List (EDL) which included over 300 commonly used pharmaceuticals that will be subsidized by the government to provide easier access to all citizens. We are pleased that China Yongxin is a retailer or distributor of 295 of the products on that list. We are further encouraged by the increasing momentum toward healthcare reform and the government's efforts to boost domestic spending. During 2009, we also added 12 high margin pharmaceutical products with exclusive distribution rights in Jilin province and we expect this to drive market share gains and growth during the coming year," Mr. Liu said.
The cost of goods sold for the year is projected to be approximately $31.3 million, a significant reduction compared to $47.2 million in the prior year. This would represent an improvement in the Company's 2009 gross profit to $15.2 million and gross margin to 32.6%, compared to $11.9 million in gross profit and a gross margin of 20.1% for 2008. The projected increase in gross margins primarily was due to higher margin retail and medical facilities sales.
Operating expenses for 2009 are projected to be approximately $6.8 million, compared to $6.1 million in 2008. Selling expenses for the year are projected to decrease slightly from the prior year to $3.4 million. The Company prudently managed utilities usage, transportation costs and sales people to effectively reduce selling expense and maintain gross profit. General and administrative expenses for 2009 are projected to increase approximately 30.8% to $3.4 million, compared to $2.6 million in 2008. The majority of the increase is related to litigation expenses and consulting service expenses.
Income from operations projected for 2009 is approximately $8.3 million, a 43% increase from the $5.8 million for 2008. Operating margins are expected to be 18% and 9.8% for 2009 and 2008, respectively.
Business Development
On March 9, China Yongxin formally launched its Electronic Diagnosis System, of which 20 systems have been installed so far in Yongxin chain drugstores located in Changchun, Jilin. The System enables our customers to remotely receive medical diagnosis and conveniently purchase prescription drugs at that store. The Company is always working to improve the level of service it offers and leverage its large and growing base of "Member" customers who are entitled to discounts, rebates and special offers. This strategy, in addition to selling a broader array of higher margin health, beauty and cosmetic products has increased customer retention and improved revenue and profitability in this business segment.
Since the beginning of 2009, China Yongxin has signed 12 exclusive distribution agreements for Jilin province with several well known pharmaceutical manufacturers including Tianjin Smith Kline & French Laboratones Ltd. As of June 30, China Yongxin has approximately 216 drugs with exclusive distribution rights in Jilin province. This portfolio is a key component of its long-term growth strategy to leverage the large distribution center and channels established to drive incremental future revenue growth. These agreements are typically one year in duration and are renewable.
China Yongxin recently secured loans from local banks and rural credit unions totaling $2.9 million, with terms ranging from 1 to 3 years, renewable after the initial terms. Loan proceeds will be used to provide working capital for the Company's distribution segment as it capitalizes on new organic growth opportunities supported by the government's new healthcare initiative.
Mr. Liu further commented, "With enhanced government support, specifically the commencement of China's $126 billion health care reform plan focused on providing a broader spectrum of healthcare services and pharmaceutical products to all Chinese residents, we are confident that our modernized logistics center and distribution channels, the broad customer base of our chain drugstores, our extensive product portfolio, and committed management team will enable us to resume our growth momentum and capitalize on a long-term, secular growth opportunity," Mr. Liu concluded.
About China Yongxin Pharmaceuticals, Inc.
China Yongxin Pharmaceuticals, Inc. was founded in 1993 as the Changchun Yongxin Dirui Medical Co., Ltd. (Yongxin), is a manufacturer, retailer and distributor of Chinese traditional medicines, pharmaceutical preparations, natural health products, health food, cosmetics, and medical equipment in Northeastern China. It began retail operations in 2004, and in 2005, it gained franchise rights from one of the world's largest drug chains for China's Jilin Province. By the end of 2007, the Company had become one of the fastest growing drug retailers in China through its retail chain of 93 drug outlets as well as wholesale distribution and manufacturing operations in Northeastern China. For more information about China Yongxin Pharmaceuticals, please visit http://www.yongxinchina.com .
Forward Looking Statements
This news release contains certain "forward-looking statements." Forward-looking statements are based on current expectations and assumptions and are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified, and many of which are beyond the Company's control. The forward-looking statements are also identified through the use of words "believe," enable," "may," "will," "could," "intends," "estimate," "anticipate," "plan," "predict" "probable," "potential," "possible," "should," "continue," "project", "expect" and other words of similar meaning. Actual results could differ materially from these forward-looking statements as a result of a number of risk factors detailed in the Company's periodic reports filed with the SEC. Given these risks and uncertainties, investors are cautioned not to place undue reliance on such forward-looking statements and no assurances can be given that such statements will be achieved. China Yongxin Pharmaceutical Inc. does not assume any duty to publicly update or revise the material contained herein.
For more information, please contact: For the Company: Mr. Sam Liu, COO China Yongxin Pharmaceuticals, Inc. Tel: +1-626-581-9098 Email: info@yongxinchina.com Investors: Mr. Matthew Hayden, HC International Tel: +1-561-245-5155 Email: matt.hayden@hcinternational.net Web: http://www.hcinternational.net
Super cheap here imho...tuna
In Chinese CYXN .59 +.03 w/.16 net income for '09 estimated:
China Yongxin Pharmaceuticals Projects Higher Net Income and EPS on Reduced Revenue for Full-Year 2009
Year End Will Show Higher Gross Profit and Margins Due to Change in Strategy
Press Release Source: China Yongxin Pharmaceuticals, Inc. On Thursday December 31, 2009, 8:00 am EST
CHANGCHUN, China and LOS ANGELES, Dec. 31 /PRNewswire-Asia/ -- China Yongxin Pharmaceuticals, Inc. (OTC Bulletin Board: CYXN; "China Yongxin Pharmaceuticals" or the "Company"), a leading manufacturer, distributor and retailer of Chinese traditional medicines, pharmaceutical products, natural health products, health food, cosmetics, and medical equipment in Northeastern China, today announced its projected financial results for the year ending December 31, 2009.
Revenues for the full-year 2009 are projected to be $46.1 million, a 22% decrease from $59.1 million for 2008. The decrease in total revenue is due to the transition of the Company's sales strategy, which, because of the uncertain direction of the National Medical Policy, has been refocused from the wholesale sector to the retail and medical facilities sector. While a broader product portfolio and expanded marketing activities increased 2009 revenues from the Company's retail drug stores by approximately 30% over the prior year, it was not sufficient to completely offset the decrease in the Company's wholesale business, resulting in comparably lower total net revenue.
For 2009, net income is projected to be approximately $5.4 million, a 35% increase over the $4.1 million for 2008. The increase primarily is related to higher margin retail and medical facilities sales.
The Company expects to report that diluted earnings per share increased to $0.16 for 2009 compared to $0.13 for 2008, based on 34.4 million and 31.2 million shares respectively. Provision for income tax in 2009 is $2.7 million compared to $1 million in 2008.
Mr. Yongxin Liu, Chairman and Chief Executive Officer of China Yongxin, commented that during 2009, the Company's wholesale business was impacted by customers waiting for specifics on the new healthcare reform plan. "However, on August 18th, the Chinese government issued China's Essential Drug List (EDL) which included over 300 commonly used pharmaceuticals that will be subsidized by the government to provide easier access to all citizens. We are pleased that China Yongxin is a retailer or distributor of 295 of the products on that list. We are further encouraged by the increasing momentum toward healthcare reform and the government's efforts to boost domestic spending. During 2009, we also added 12 high margin pharmaceutical products with exclusive distribution rights in Jilin province and we expect this to drive market share gains and growth during the coming year," Mr. Liu said.
The cost of goods sold for the year is projected to be approximately $31.3 million, a significant reduction compared to $47.2 million in the prior year. This would represent an improvement in the Company's 2009 gross profit to $15.2 million and gross margin to 32.6%, compared to $11.9 million in gross profit and a gross margin of 20.1% for 2008. The projected increase in gross margins primarily was due to higher margin retail and medical facilities sales.
Operating expenses for 2009 are projected to be approximately $6.8 million, compared to $6.1 million in 2008. Selling expenses for the year are projected to decrease slightly from the prior year to $3.4 million. The Company prudently managed utilities usage, transportation costs and sales people to effectively reduce selling expense and maintain gross profit. General and administrative expenses for 2009 are projected to increase approximately 30.8% to $3.4 million, compared to $2.6 million in 2008. The majority of the increase is related to litigation expenses and consulting service expenses.
Income from operations projected for 2009 is approximately $8.3 million, a 43% increase from the $5.8 million for 2008. Operating margins are expected to be 18% and 9.8% for 2009 and 2008, respectively.
Business Development
On March 9, China Yongxin formally launched its Electronic Diagnosis System, of which 20 systems have been installed so far in Yongxin chain drugstores located in Changchun, Jilin. The System enables our customers to remotely receive medical diagnosis and conveniently purchase prescription drugs at that store. The Company is always working to improve the level of service it offers and leverage its large and growing base of "Member" customers who are entitled to discounts, rebates and special offers. This strategy, in addition to selling a broader array of higher margin health, beauty and cosmetic products has increased customer retention and improved revenue and profitability in this business segment.
Since the beginning of 2009, China Yongxin has signed 12 exclusive distribution agreements for Jilin province with several well known pharmaceutical manufacturers including Tianjin Smith Kline & French Laboratones Ltd. As of June 30, China Yongxin has approximately 216 drugs with exclusive distribution rights in Jilin province. This portfolio is a key component of its long-term growth strategy to leverage the large distribution center and channels established to drive incremental future revenue growth. These agreements are typically one year in duration and are renewable.
China Yongxin recently secured loans from local banks and rural credit unions totaling $2.9 million, with terms ranging from 1 to 3 years, renewable after the initial terms. Loan proceeds will be used to provide working capital for the Company's distribution segment as it capitalizes on new organic growth opportunities supported by the government's new healthcare initiative.
Mr. Liu further commented, "With enhanced government support, specifically the commencement of China's $126 billion health care reform plan focused on providing a broader spectrum of healthcare services and pharmaceutical products to all Chinese residents, we are confident that our modernized logistics center and distribution channels, the broad customer base of our chain drugstores, our extensive product portfolio, and committed management team will enable us to resume our growth momentum and capitalize on a long-term, secular growth opportunity," Mr. Liu concluded.
About China Yongxin Pharmaceuticals, Inc.
China Yongxin Pharmaceuticals, Inc. was founded in 1993 as the Changchun Yongxin Dirui Medical Co., Ltd. (Yongxin), is a manufacturer, retailer and distributor of Chinese traditional medicines, pharmaceutical preparations, natural health products, health food, cosmetics, and medical equipment in Northeastern China. It began retail operations in 2004, and in 2005, it gained franchise rights from one of the world's largest drug chains for China's Jilin Province. By the end of 2007, the Company had become one of the fastest growing drug retailers in China through its retail chain of 93 drug outlets as well as wholesale distribution and manufacturing operations in Northeastern China. For more information about China Yongxin Pharmaceuticals, please visit http://www.yongxinchina.com .
Forward Looking Statements
This news release contains certain "forward-looking statements." Forward-looking statements are based on current expectations and assumptions and are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified, and many of which are beyond the Company's control. The forward-looking statements are also identified through the use of words "believe," enable," "may," "will," "could," "intends," "estimate," "anticipate," "plan," "predict" "probable," "potential," "possible," "should," "continue," "project", "expect" and other words of similar meaning. Actual results could differ materially from these forward-looking statements as a result of a number of risk factors detailed in the Company's periodic reports filed with the SEC. Given these risks and uncertainties, investors are cautioned not to place undue reliance on such forward-looking statements and no assurances can be given that such statements will be achieved. China Yongxin Pharmaceutical Inc. does not assume any duty to publicly update or revise the material contained herein.
For more information, please contact: For the Company: Mr. Sam Liu, COO China Yongxin Pharmaceuticals, Inc. Tel: +1-626-581-9098 Email: info@yongxinchina.com Investors: Mr. Matthew Hayden, HC International Tel: +1-561-245-5155 Email: matt.hayden@hcinternational.net Web: http://www.hcinternational.net
Super cheap here imho...tuna
Chinese CYXN .59 +.03 estimates to earn .16 for '09!!! SUPER CHEAP at this level imho...here's PR with expectations for '09:
China Yongxin Pharmaceuticals Projects Higher Net Income and EPS on Reduced Revenue for Full-Year 2009
Year End Will Show Higher Gross Profit and Margins Due to Change in Strategy
Press Release Source: China Yongxin Pharmaceuticals, Inc. On Thursday December 31, 2009, 8:00 am EST
CHANGCHUN, China and LOS ANGELES, Dec. 31 /PRNewswire-Asia/ -- China Yongxin Pharmaceuticals, Inc. (OTC Bulletin Board: CYXN; "China Yongxin Pharmaceuticals" or the "Company"), a leading manufacturer, distributor and retailer of Chinese traditional medicines, pharmaceutical products, natural health products, health food, cosmetics, and medical equipment in Northeastern China, today announced its projected financial results for the year ending December 31, 2009.
Revenues for the full-year 2009 are projected to be $46.1 million, a 22% decrease from $59.1 million for 2008. The decrease in total revenue is due to the transition of the Company's sales strategy, which, because of the uncertain direction of the National Medical Policy, has been refocused from the wholesale sector to the retail and medical facilities sector. While a broader product portfolio and expanded marketing activities increased 2009 revenues from the Company's retail drug stores by approximately 30% over the prior year, it was not sufficient to completely offset the decrease in the Company's wholesale business, resulting in comparably lower total net revenue.
For 2009, net income is projected to be approximately $5.4 million, a 35% increase over the $4.1 million for 2008. The increase primarily is related to higher margin retail and medical facilities sales.
The Company expects to report that diluted earnings per share increased to $0.16 for 2009 compared to $0.13 for 2008, based on 34.4 million and 31.2 million shares respectively. Provision for income tax in 2009 is $2.7 million compared to $1 million in 2008.
Mr. Yongxin Liu, Chairman and Chief Executive Officer of China Yongxin, commented that during 2009, the Company's wholesale business was impacted by customers waiting for specifics on the new healthcare reform plan. "However, on August 18th, the Chinese government issued China's Essential Drug List (EDL) which included over 300 commonly used pharmaceuticals that will be subsidized by the government to provide easier access to all citizens. We are pleased that China Yongxin is a retailer or distributor of 295 of the products on that list. We are further encouraged by the increasing momentum toward healthcare reform and the government's efforts to boost domestic spending. During 2009, we also added 12 high margin pharmaceutical products with exclusive distribution rights in Jilin province and we expect this to drive market share gains and growth during the coming year," Mr. Liu said.
The cost of goods sold for the year is projected to be approximately $31.3 million, a significant reduction compared to $47.2 million in the prior year. This would represent an improvement in the Company's 2009 gross profit to $15.2 million and gross margin to 32.6%, compared to $11.9 million in gross profit and a gross margin of 20.1% for 2008. The projected increase in gross margins primarily was due to higher margin retail and medical facilities sales.
Operating expenses for 2009 are projected to be approximately $6.8 million, compared to $6.1 million in 2008. Selling expenses for the year are projected to decrease slightly from the prior year to $3.4 million. The Company prudently managed utilities usage, transportation costs and sales people to effectively reduce selling expense and maintain gross profit. General and administrative expenses for 2009 are projected to increase approximately 30.8% to $3.4 million, compared to $2.6 million in 2008. The majority of the increase is related to litigation expenses and consulting service expenses.
Income from operations projected for 2009 is approximately $8.3 million, a 43% increase from the $5.8 million for 2008. Operating margins are expected to be 18% and 9.8% for 2009 and 2008, respectively.
Business Development
On March 9, China Yongxin formally launched its Electronic Diagnosis System, of which 20 systems have been installed so far in Yongxin chain drugstores located in Changchun, Jilin. The System enables our customers to remotely receive medical diagnosis and conveniently purchase prescription drugs at that store. The Company is always working to improve the level of service it offers and leverage its large and growing base of "Member" customers who are entitled to discounts, rebates and special offers. This strategy, in addition to selling a broader array of higher margin health, beauty and cosmetic products has increased customer retention and improved revenue and profitability in this business segment.
Since the beginning of 2009, China Yongxin has signed 12 exclusive distribution agreements for Jilin province with several well known pharmaceutical manufacturers including Tianjin Smith Kline & French Laboratones Ltd. As of June 30, China Yongxin has approximately 216 drugs with exclusive distribution rights in Jilin province. This portfolio is a key component of its long-term growth strategy to leverage the large distribution center and channels established to drive incremental future revenue growth. These agreements are typically one year in duration and are renewable.
China Yongxin recently secured loans from local banks and rural credit unions totaling $2.9 million, with terms ranging from 1 to 3 years, renewable after the initial terms. Loan proceeds will be used to provide working capital for the Company's distribution segment as it capitalizes on new organic growth opportunities supported by the government's new healthcare initiative.
Mr. Liu further commented, "With enhanced government support, specifically the commencement of China's $126 billion health care reform plan focused on providing a broader spectrum of healthcare services and pharmaceutical products to all Chinese residents, we are confident that our modernized logistics center and distribution channels, the broad customer base of our chain drugstores, our extensive product portfolio, and committed management team will enable us to resume our growth momentum and capitalize on a long-term, secular growth opportunity," Mr. Liu concluded.
About China Yongxin Pharmaceuticals, Inc.
China Yongxin Pharmaceuticals, Inc. was founded in 1993 as the Changchun Yongxin Dirui Medical Co., Ltd. (Yongxin), is a manufacturer, retailer and distributor of Chinese traditional medicines, pharmaceutical preparations, natural health products, health food, cosmetics, and medical equipment in Northeastern China. It began retail operations in 2004, and in 2005, it gained franchise rights from one of the world's largest drug chains for China's Jilin Province. By the end of 2007, the Company had become one of the fastest growing drug retailers in China through its retail chain of 93 drug outlets as well as wholesale distribution and manufacturing operations in Northeastern China. For more information about China Yongxin Pharmaceuticals, please visit http://www.yongxinchina.com .
Forward Looking Statements
This news release contains certain "forward-looking statements." Forward-looking statements are based on current expectations and assumptions and are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified, and many of which are beyond the Company's control. The forward-looking statements are also identified through the use of words "believe," enable," "may," "will," "could," "intends," "estimate," "anticipate," "plan," "predict" "probable," "potential," "possible," "should," "continue," "project", "expect" and other words of similar meaning. Actual results could differ materially from these forward-looking statements as a result of a number of risk factors detailed in the Company's periodic reports filed with the SEC. Given these risks and uncertainties, investors are cautioned not to place undue reliance on such forward-looking statements and no assurances can be given that such statements will be achieved. China Yongxin Pharmaceutical Inc. does not assume any duty to publicly update or revise the material contained herein.
For more information, please contact: For the Company: Mr. Sam Liu, COO China Yongxin Pharmaceuticals, Inc. Tel: +1-626-581-9098 Email: info@yongxinchina.com Investors: Mr. Matthew Hayden, HC International Tel: +1-561-245-5155 Email: matt.hayden@hcinternational.net Web: http://www.hcinternational.net
tuna
Appreciate it WANG! tuna
Thanks...will get TAYD on the streamer wick! tuna
Chinese NEWN 7.20 +.10 at HOD ut'ing now!
Chinese CREG 6.16 +.98 HOD probably it's biggest volume ever, for sure way beyond anything of the last 6 month chart! Backed off to 5.98 here...tuna
Interesting on FUQI too after the huge fall...thanks! tuna
CHGY was another great pick of yours!! Congrats...tuna
Thanks wick on CREG...love the upside due to it's fast revenue and earnings growth!!
Thanks wick for the info on MILL...appreciate it! CREG 6.16 +.96 new HOD by the way on my Chinese newly uplisted stock today on massive volume, probably the most in their trading history...for sure way beyond anything in the last 6 months...tuna
Yes WANG...CREG 6.16 +.98 is the new HOD now!!
And I believe Chinese NEWN 7.10 will also uplist soon and they're estimating earnings of $1.23 I believe if memory serves...so another very low PE Chinese stock which is growing rapidly...I love these stocks!! Haha!! tuna
Thanks wick...I agree! Probably uplist like CREG did before long also imho...tuna
CGAQ now up to .102 on the ask...come on a break .11 today!!
APT 3.45 +.08 HOD acting much better recently after a strong earnings report a couple of weeks back...tuna